The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

Aging Cell

Volumn 14, Issue 5, 2015, Pages 715-724

  Deger, Jennifer M ^a   Gerson, Julia E ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer's disease; Covalent modification; Huntington's disease; Neurodegeneration; Parkinson's disease; Small ubiquitin like modifiers; Tau oligomers; Tauopathies; Ubiquitin proteasome system; Ubiquitination

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; HUNTINGTIN; PROTEASOME; TAU PROTEIN;

COVALENT BOND; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; MOLECULAR THERAPY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SUMOYLATION; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION; ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; METABOLISM; MOLECULAR MODEL;

ANIMALS; HUMANS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TAU PROTEINS;

EID: 84940895961     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12359     Document Type: Review

References (112)

1. Adams J, Kauffman M (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304-311.
2. Almeida CG, Takahashi RH, Gouras GK (2006) β-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 26, 4277-4288.
3. Alonso AC, Li B, Grundke-Iqbal I, Iqbal K (2008) Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 5, 375-384.
4. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME (1998) Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 21, 516-520.
5. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
6. Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M (1999) Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843, 53-61.
7. Avila J (2000) Tau aggregation into fibrillar polymers: taupathies. FEBS Lett. 476, 89-92.
8. Ayaydin F, Dasso M (2004) Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol. Biol. Cell 15, 5208-5218.
9. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555.
10. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662.
11. Biernat J, Gustke N, Drewes G, Mandelkow E, Mandelkow E (1993) Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11, 153-163.
12. Bohren KM, Gabbay KH, Owerbach D (2007) Affinity chromatography of native SUMO proteins using His-tagged recombinant UBC9 bound to Co2+-charged talon resin. Protein Expr. Purif. 54, 289-294.
13. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VMY (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10, 1089-1099.
14. Bretteville A, Planel E (2008) Tau aggregates: toxic, inert, or protective species? J. Alzheimers Dis. 14, 431-436.
15. Brunden KR, Trojanowski JQ, Lee VM (2008) Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimer's Dis. 14, 393-399.
16. Cammarata S, Caponnetto C, Tabaton M (1993) Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: a pathological correlate of dementia? Neurosci. Lett. 156, 96-98.
17. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R (2014a) Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J. Alzheimers Dis. 40(Suppl 1), S97-S111.
18. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R (2013) Tau aggregates as immunotherapeutic targets. Front. Biosci. (Schol Ed). 5, 426-438.
19. Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett ADT, Dineley KT, Jackson GR, Kayed R (2014b) Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272.
20. Chen P-C, Bhattacharyya BJ, Hanna J, Minkel H, Wilson JA, Finley D, Miller RJ, Wilson SM (2011) Ubiquitin homeostasis is critical for synaptic development and function. J. Neurosci. 31, 17505-17513.
21. Chen P-C, Qin L-N, Li X-M, Walters BJ, Wilson JA, Mei L, Wilson SM (2009) The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J. Neurosci. 29, 10909-10919.
22. Chen Y, Li YJ (2012) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use. Google Patents.
23. Clayton DF, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129.
24. Constantinescu R, Romer M, Zetterberg H, Rosengren L, Kieburtz K (2011) Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. Parkinsonism Relat. Disord. 17, 714-715.
25. Cook WJ, Jeffrey LC, Kasperek E, Pickart CM (1994) Structure of tetraubiquitin shows how multiubiquitin chains can be formed. J. Mol. Biol. 236, 601-609.
26. Davidowitz E, Chatterjee I, Moe J (2008) Targeting tau oligomers for therapeutic development for Alzheimer's disease and tauopathies. Curr. Topics Biol. 4, 47-64.
27. de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol. 74, 249-270.
28. Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buee L (2005) Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett. 579, 1-5.
29. Desterro JM, Keegan LP, Jaffray E, Hay RT, O'Connell MA, Carmo-Fonseca M (2005) SUMO-1 modification alters ADAR1 editing activity. Mol. Biol. Cell 16, 5115-5126.
30. Dorval V, Fraser PE (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 281, 9919-9924.
31. Dunker AK, Silman I, Uversky VN, Sussman JL (2008) Function and structure of inherently disordered proteins. Curr. Opin. Struct. Biol. 18, 756-764.
32. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
33. Fernagut PO, Chesselet MF (2004) Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123-130.
34. Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernandez F, Avila J, Lucas JJ (2014) Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat. Med. 20, 881-885.
35. Field-Smith A, Morgan GJ, Davies FE (2006) Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther. Clin. Risk Manag. 2, 271-279.
36. Reggiori F, Komatsu M, Finley K, Simonsen A (2012) Autophagy: more than a nonselective pathway. Int. J. Cell Biol. 2012, 18.
37. Gerson JE, Castillo-Carranza DL, Kayed R (2014a) Advances in therapeutics for neurodegenerative tauopathies: moving towards the specific targeting of the most toxic tau species. ACS Chem. Neurosci. 5, 752-769.
38. Gerson JE, Kayed R (2013b) Formation and propagation of tau oligomeric seeds. Front. Neurol. 4, 93.
39. Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Munoz MJ, Troncoso J, Kayed R (2014b) Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2, 73.
40. Giasson BI, Lee VM, Trojanowski JQ (2003) Interactions of amyloidogenic proteins. Neuromolecular Med. 4, 49-58.
41. Gill G (2004) SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18, 2046-2059.
42. Girdwood DW, Tatham MH, Hay RT (2004) SUMO and transcriptional regulation. Semin. Cell Dev. Biol. 15, 201-210.
43. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA (2001) From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 213-227.
44. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899.
45. Guerrero-Munoz MJ, Castillo-Carranza DL, Kayed R (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol. 88, 468-478.
46. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
47. Hallengren J, Chen P-C, Wilson S (2013) Neuronal ubiquitin homeostasis. Cell Biochem. Biophys. 67, 67-73.
48. Harada T, Harada C, Wang YL, Osaka H, Amanai K, Tanaka K, Takizawa S, Setsuie R, Sakurai M, Sato Y, Noda M, Wada K (2004) Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am. J. Pathol. 164, 59-64.
49. Hay RT (2005) SUMO: a history of modification. Mol. Cell 18, 1-12.
50. Hochstrasser M (1996) Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30, 405-439.
51. Holmes BB, Diamond MI (2014) Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J. Biol. Chem. 289, 19855-19861.
52. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl Acad. Sci. USA 100, 6370-6375.
53. Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
54. Johnson ES (2004) Protein modification by SUMO. Annu. Rev. Biochem. 73, 355-382.
55. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR (1996) Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271, 19385-19394.
56. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A (1988) Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23, 138-144.
57. Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33(Suppl 1), S67-S78.
58. Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85, 115-122.
59. Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268, 24374-24384.
60. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I (1994) Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res. 639, 1-7.
61. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R (2000) Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 9902-9906.
62. Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 5, 958-963.
63. Lang AE, Lozano AM (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med. 339, 1130-1143.
64. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012a) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959.
65. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R (2012b) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959.
66. Lee MJ, Lee JH, Rubinsztein DC (2013) Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog. Neurobiol. 105, 49-59.
67. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
68. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson's disease. Int. J. Biochem. Cell Biol. 42, 1775-1778.
69. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
70. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
71. Manczak M, Reddy PH (2013) Abnormal interaction of oligomeric amyloid-beta with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J. Alzheimers Dis. 36, 285-295.
72. Martins-Branco D, Esteves AR, Santos D, Arduino DM, Swerdlow RH, Oliveira CR, Januario C, Cardoso SM (2012) Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness? Exp. Neurol. 238, 89-99.
73. Marx J (2007) Alzheimer's disease. A new take on tau. Science 316, 1416-1417.
74. Mayer RJ, Tipler C, Arnold J, Laszlo L, Al-Khedhairy A, Lowe J, Landon M (1996) Endosome-lysosomes, ubiquitin and neurodegeneration. Adv. Exp. Med. Biol. 389, 261-269.
75. McClellan AJ, Frydman J (2001) Molecular chaperones and the art of recognizing a lost cause. Nat. Cell Biol. 3, E51-E53.
76. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46.
77. Melchior F (2000) SUMO-nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16, 591-626.
78. Metcalfe MJ, Huang Q, Figueiredo-Pereira ME (2012) Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP. Cell Death Dis. 3, e326.
79. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Watanabe A, Titani K, Ihara Y (1995) Hyperphosphorylation of tau in PHF. Neurobiol. Aging 16, 365-371; discussion 371-380.
80. Olanow CW, McNaught KS (2006) Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21, 1806-1823.
81. Park H-J, Kim S-S, Kang S, Rhim H (2009) Intracellular Aβ and C99 aggregates induce mitochondria-dependent cell death in human neuroglioma H4 cells through recruitment of the 20S proteasome subunits. Brain Res. 1273, 1-8.
82. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl), S10-S17.
83. Rubin GM, Yandell MD, Wortman JR, Gabor Miklos GL, Nelson CR, Hariharan IK, Fortini ME, Li PW, Apweiler R, Fleischmann W, Cherry JM, Henikoff S, Skupski MP, Misra S, Ashburner M, Birney E, Boguski MS, Brody T, Brokstein P, Celniker SE, Chervitz SA, Coates D, Cravchik A, Gabrielian A, Galle RF, Gelbart WM, George RA, Goldstein LS, Gong F, Guan P, Harris NL, Hay BA, Hoskins RA, Li J, Li Z, Hynes RO, Jones SJ, Kuehl PM, Lemaitre B, Littleton JT, Morrison DK, Mungall C, O'Farrell PH, Pickeral OK, Shue C, Vosshall LB, Zhang J, Zhao Q, Zheng XH, Lewis S (2000) Comparative genomics of the eukaryotes. Science 287, 2204-2215.
84. Saitoh H, Hinchey J (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252-6258.
85. Sarge KD, Park-Sarge OK (2009) Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 34, 200-205.
86. Schiffer D, Attanasio A, Chio A, Migheli A, Pezzulo T (1994) Ubiquitinated dystrophic neurites suggest corticospinal derangement in patients with amyotrophic lateral sclerosis. Neurosci. Lett. 180, 21-24.
87. Selkoe DJ (2013) SnapShot: pathobiology of Alzheimer's disease. Cell 154, 468-468.e1.
88. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K (1998) Phosphorylation of Tau at Both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309.
89. Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR, Kayed R (2015) Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol. Psychiatry pii: S0006-3223(15)00003-7.
90. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897-4902.
91. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
92. Song S, Jung YK (2004) Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol. Med. 10, 565-570.
93. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473.
94. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT (2009) Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 32, 150-159.
95. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100-104.
96. Sugiyama H, Hainfellner JA, Yoshimura M, Budka H (1994) Neocortical changes in Parkinson's disease, revisited. Clin. Neuropathol. 13, 55-59.
97. Taddei N, Liguri G, Sorbi S, Amaducci L, Camici G, Nassi P, Cecchi C, Ramponi G (1993) Cerebral soluble ubiquitin is increased in patients with Alzheimer's disease. Neurosci. Lett. 151, 158-161.
98. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 181, 1426-1435.
99. Takahashi K, Ishida M, Komano H, Takahashi H (2008) SUMO-1 immunoreactivity co-localizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci. Lett. 441, 90-93.
100. Terry RD (2001) An honorable compromise regarding amyloid in Alzheimer disease. Ann. Neurol. 49, 684.
101. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44, 415-422.
102. Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, Trejo M, Crews L, Paulino A, Moessler H, Masliah E (2009) Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol. 117, 699-712.
103. Ulrich HD (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 15, 525-532.
104. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J. Neurosci. Res. 89, 1031-1042.
105. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 14, 95-104.
106. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI (2006) Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell Proteomics 5, 2298-2310.
107. Vidal RL, Matus S, Bargsted L, Hetz C (2014) Targeting autophagy in neurodegenerative diseases. Trends Pharmacol. Sci. 35, 583-591.
108. Walker LC, Diamond MI, Duff KE, Hyman BT (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 70, 304-310.
109. Wang J, Maldonado MA (2006) The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell. Mol. Immunol. 3, 255-261.
110. Wang Y, Dasso M (2009) SUMOylation and deSUMOylation at a glance. J. Cell Sci. 122, 4249-4252.
111. Zhang J, Goodson ML, Hong Y, Sarge KD (2008) MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation. J. Biol. Chem. 283, 7464-7469.
112. Zhang J, Hattori N, Giladi N, Mizuno Y (2000) Failure to find mutations in ubiquitin carboxy-terminal hydrolase L1 gene in familial Parkinson's disease. Parkinsonism Relat. Disord. 6, 199-200.